Home > News Center > Saudi Arabia Medical Device Registration: 23 SFDA FAQs on MDMA, Reliance and 2026 Updates

Saudi Arabia Medical Device Registration: 23 SFDA FAQs on MDMA, Reliance and 2026 Updates

Nov 10, 2026 Registration Insights 0 views

Saudi Arabia is a major medical device market in the Middle East. In recent years, the Saudi Food and Drug Authority (SFDA) has continuously updated its requirements on medical device marketing authorization, product bundling, reliance review, advertising approval, quality systems, and import clearance. Based on SFDA regulations, guidance documents, announcements, and official fee documents published for public reference, this article organizes the key questions on the Saudi medical device marketing authorization (MDMA).

This article highlights the requirements that are new or updated in 2026. Classification, application pathways, and documentation requirements may vary from product to product; for any specific project, the product’s intended use, risk class, applicable regulations, and the actual requirements of the GHAD system shall prevail.

Part 1: Regulatory Framework and Market Access Basics

Q1 Which authority regulates medical devices in Saudi Arabia, and what are the main legal bases?

Medical devices in Saudi Arabia are regulated by the Medical Devices Sector (MDS) of the Saudi Food and Drug Authority (SFDA).

The current regulatory framework mainly includes:

  • The Medical Devices Law, issued by Royal Decree No. M/54 on 7 June 1442H;
  • The Implementing Regulation of the Medical Devices Law, adopted by SFDA Board Resolution No. (3-29-1443) dated 19 February 1443H;
  • Medical device regulatory requirements issued by SFDA (the MDS-REQ series), covering marketing authorization, clinical trials, import clearance, UDI, advertising, establishment licensing, post-market surveillance, transport, and storage;
  • Specialized guidance documents issued by SFDA (the MDS-G series), which further clarify classification, changes, product bundling, reliance review, and recognized standards.

Key 2026 documents to watch closely include:

DocumentMain ContentVersion / Publication Date
MDS-G028Bundling criteria for products within a single MDMA applicationV1.0, 2026-05-03
MDS-REQ8Medical device advertising approval and awareness or charitable campaignsV4.0, 2026-07-20
MDS-G030SFDA reliance approach for medical devicesV1.0, 2026-09-09
MDS-G020Guidance on recognized standards for medical devices (MDMA applications)Published on the SFDA website on 2026-11-02

Q2 Which products fall under Saudi medical device regulation? Do cosmetic lasers and contact lenses also need registration?

The Saudi definition of a medical device is primarily based on the manufacturer’s intended use and the principal mechanism of action by which the product achieves its intended function. Medical devices include instruments, apparatus, appliances, implants, IVD reagents or calibrators, software, and related materials; their principal intended action must not be achieved by pharmacological, immunological, or metabolic means.

Note in particular that some products without a traditional therapeutic purpose are also regulated by SFDA as medical devices. The special product list in Annex (5) of MDS-REQ1 includes:

  • Contact lenses and other related products intended for the eye;
  • Products used for filling or augmentation of the face or other body parts;
  • Devices for liposuction, fat reduction, or body shaping;
  • High-intensity electromagnetic radiation devices for skin resurfacing, tattoo removal, hair removal, and similar uses, including laser and intense pulsed light (IPL) devices;
  • Related devices intended for brain stimulation.

Therefore, cosmetic lasers, certain aesthetic devices, contact lenses, and similar products cannot be considered outside SFDA regulation simply because treating disease is not their primary purpose.

One common misconception should be corrected: the claim that ‘contact lenses containing hydrating agents are classified as Class C’ cannot be taken as a general classification conclusion for contact lenses as such. Contact lenses, contact lens care products, and related products must each be assessed separately against the applicable special product requirements and classification rules. Contact lenses and care products are also covered by the dedicated SFDA guidance MDS-G40.

[Legal basis] Annex (5) and Annex (16) of MDS-REQ1 V6.0; SFDA guidance MDS-G40 on contact lenses and care products.

Q3 Can medical devices be sold in Saudi Arabia without an MDMA? What is an MDMA?

Medical devices entering the Saudi market for commercial distribution must in principle obtain a Medical Device Marketing Authorization (MDMA) issued by SFDA.

Without the applicable MDMA, a product must not be sold or distributed in Saudi Arabia as an approved medical device through normal commercial channels.

The MDMA primarily confirms that a product has been authorized for marketing by SFDA. The certificate typically includes:

  • Manufacturer information;
  • Identification of the device or device group;
  • The Saudi National Listing Number assigned to the product;
  • The MDMA certificate number;
  • The validity period of the certificate.

It should be distinguished that Saudi regulations also provide for special import scenarios such as clinical trials, research and education, exhibition and display, personal use, and humanitarian use. These scenarios require the corresponding license or procedures under MDS-REQ5. A special-purpose import authorization is not a commercial marketing authorization and cannot replace the MDMA required for normal commercial distribution.

[Legal basis] Article 1 and Article 4 of MDS-REQ1 V6.0 and related annexes; MDS-REQ5 V6.0.

Q4 How are medical devices classified in Saudi Arabia? Is it the same as the EU CE classification?

Saudi Arabia uses a four-tier risk classification of Class A, B, C, and D:

  • Class A: low risk;
  • Class B: low to moderate risk;
  • Class C: higher risk;
  • Class D: highest risk.

Annex (5) of MDS-REQ1 provides:

  • Non-IVD medical devices: 22 classification rules;
  • IVD medical devices: 7 classification rules.

Classification is the responsibility of the manufacturer. Manufacturers should determine the class based on the intended use, site of use, degree of invasiveness, duration of contact, mechanism of action, and applicable special rules.

Where multiple rules apply at the same time, the class should be determined by the rule that yields the higher risk level among the applicable rules, and the classification rationale should be documented.

The Saudi classification shares some risk classification principles with the EU MDR/IVDR, but the two are not fully identical:

  • Under the EU MDR, non-IVD devices use Classes I, IIa, IIb, and III;
  • Under the EU IVDR, IVDs use Classes A, B, C, and D;
  • In Saudi Arabia, both non-IVD devices and IVDs use Classes A, B, C, and D.

Therefore, the class shown on a CE certificate cannot be directly converted into an SFDA class; classification must be reassessed under the Saudi MDS-REQ1 and the classification guidance.

[Legal basis] Article 4 and Annex (5) of MDS-REQ1 V6.0; SFDA Medical Device Classification Guidance (MDS-G008).

Q5 With a CE certificate or US FDA approval, is a new technical review still required in Saudi Arabia?

Not necessarily. It is important to distinguish the former reference-country simplified pathway from the reliance mechanism newly issued in 2026.

SFDA previously applied a simplified submission arrangement tied to reference countries; the related transitional arrangements ended on 1 January 2022. On 9 September 2026, SFDA issued the new MDS-G030 V1.0, ‘SFDA Reliance Approach for Medical Devices’ – the guidance on the reliance review mechanism for medical devices.

This guidance allows eligible products to leverage conformity assessment results already completed by recognized regulatory authorities, reducing duplicated review work and certain documentation submission requirements.

The recognized regulatory authorities (RRAs) currently listed in the guidance are:

Country / RegionRegulatory Authority
AustraliaTGA
CanadaHealth Canada
EU / EEACompetent authorities of EEA member states
JapanPMDA
United KingdomMHRA
United StatesFDA

Products applying for reliance review must meet the following basic conditions:

  • A valid marketing approval or license issued by at least one recognized regulatory authority;
  • Consistency in design, manufacturing process, intended use, and other technical aspects between the product submitted in Saudi Arabia and the product approved by the reference authority;
  • Compliance with applicable local Saudi requirements, including electrical requirements, labelling, IFU, user interface language, and transport and storage requirements;
  • Submission of valid evidence of the reference authority’s approval and the Reliance Form required by SFDA;
  • Completion of product classification and submission of the application dossier as required by SFDA.

Reliance review does not apply, or may not apply, in the following situations:

  • Products approved only through manufacturer self-registration or self-declaration, without independent assessment;
  • Products approved mainly by demonstrating substantial equivalence to a comparator device;
  • Custom-made medical devices;
  • Products subject to significant post-market safety issues, recalls, suspension, or revocation and other regulatory restrictions;
  • SaMD and AI-based medical devices may be excluded depending on intended use, risk, novelty, and complexity, at the discretion of SFDA.

MDS-G030 also states that SFDA accepts MDSAP certificates and audit reports issued by MDSAP auditing organizations as evidence of quality management system conformity.

The standard review timeline for reliance review is 35-60 working days; where the conditions are met and the dossier is complete, the review can be shortened to 35 working days.

Note in particular: reliance review is not an exemption from review, and not every CE certificate or FDA document qualifies directly. The reference approval, product consistency, and eligibility conditions should be verified before deciding on this pathway.

[Legal basis] SFDA MDS-G030 V1.0 (2026-09-09).

Part 2: Registration Process and Technical Requirements

Q6 Can foreign manufacturers apply for the MDMA themselves? Is a Saudi Authorized Representative (AR) mandatory?

Foreign manufacturers may submit MDMA applications through the GHAD system in accordance with SFDA requirements, or may appoint a Saudi Authorized Representative (AR) to handle the application on their behalf.

However, the following distinctions are important:

  • Who submits the MDMA application: either a qualifying foreign manufacturer or its Saudi AR;
  • AR arrangement for foreign manufacturers: under MDS-REQ9 and related requirements, foreign manufacturers should appoint an SFDA-licensed AR for their device category or general product group;
  • Commercial importation: importer licensing, applicable AR licensing, and customs clearance requirements for the goods must also be met.

Therefore, submitting the MDMA directly as a foreign manufacturer does not mean the AR licensing and related regulatory obligations can be ignored. For products meeting specific low-risk conditions, the corresponding exemption provisions should be checked further.

MDMA applications are submitted through the SFDA electronic services system (GHAD), with the application information completed according to the application type and the required documents uploaded.

[Legal basis] Article 3 and Article 4 of MDS-REQ1 V6.0; MDS-REQ9 V2.0; MDS-REQ5 V6.0.

Q7 What role does the Saudi AR play? How many ARs can be appointed at the same time? What should be noted when changing the AR?

The AR is a local legal entity in Saudi Arabia designated by the foreign manufacturer to perform the relevant regulatory obligations in Saudi Arabia on the manufacturer’s behalf, under the manufacturer’s written authorization.

The main requirements include:

  • For the same device category or general product group of the same manufacturer, more than one AR cannot be appointed at the same time;
  • The AR must obtain the corresponding SFDA establishment license;
  • The AR agreement should define the scope of authorization, the device categories or product groups involved, the responsibilities of both parties, and the term of the agreement;
  • The AR should support the manufacturer in fulfilling obligations for post-market surveillance, complaints, adverse events, and FSCA;
  • When changing the AR, the manufacturer should promptly appoint a new AR, transfer the existing obligations to the new AR, and notify SFDA;
  • The outgoing AR’s responsibilities do not terminate automatically upon unilateral termination of the agreement or expiry of its term; the outgoing AR remains responsible under the regulations until the new AR takes over or the products are no longer on the market and in use.

Official AR licensing fees:

ItemOfficial Fee
AR license2,600 SAR per year
Optional license term1-10 years

Fees are calculated based on the license term selected in the agreement between the manufacturer and the AR.

[Legal basis] MDS-REQ9 V2.0 (2025-01-15), requirements for authorized representatives and Annex (2).

Q8 What are the quality management system (QMS) requirements for manufacturers in Saudi Arabia?

Manufacturers should establish, implement, and continuously maintain an effective quality management system.

The main references include:

  • ISO 13485:2016;
  • The SFDA.MD/GSO ISO 13485:2017 standard adopted in Saudi Arabia, or an approved equivalent standard;
  • MDS-REQ10, ‘Requirements for Quality Management System Inspection and Auditing of Medical Device Manufacturers and Establishments’.

Note that Saudi Arabia imposes further requirements on QMS conformity evidence for different types of establishments:

Establishment TypeQMS Requirement
Class A and B manufacturers, importers, and distributorsMust obtain a QMS conformity certificate issued by an SFDA-designated conformity assessment body
Class C and D ARs, importers, and distributorsMay submit QMS conformity evidence upon request, or obtain an SFDA inspection report

SFDA may conduct initial inspections, licensing inspections, periodic inspections, follow-up inspections, reactive inspections, and unannounced inspections.

Therefore, companies should not rely on an ISO 13485 certificate alone; actual operating records such as quality system documentation, product technical documentation, complaint handling, risk management, CAPA, and post-market surveillance must also meet the requirements.

[Legal basis] Article 2 of MDS-REQ1 V6.0; MDS-REQ10 V2.0 (2025-01-27).

Q9 What technical documentation is required for an MDMA? Can low-risk products use a simplified submission?

The complete technical documentation is mainly organized according to Annex (3) of MDS-REQ1 (non-IVD medical devices) and Annex (4) (IVDs).

It mainly includes:

  • Product description and specifications, including models, variants, and accessories;
  • Information supplied by the manufacturer, including labelling and the IFU;
  • Design and manufacturing information;
  • The Essential Principles checklist on safety and performance;
  • Verification and validation evidence of conformity with the Essential Principles;
  • Risk management documentation and benefit-risk analysis;
  • Clinical evaluation or performance evaluation documentation;
  • The post-market surveillance plan and related reports.

Simplified submission pathway for low-risk products:

Low-risk medical devices meeting the prescribed conditions may submit six core documentation items at the initial application stage under Annex (3) of MDS-REQ1:

  • Product description and specifications;
  • Information supplied by the manufacturer;
  • The Essential Principles checklist;
  • Evidence of conformity with the applicable Essential Principles;
  • Risk management documentation;
  • The post-market surveillance plan and reports.

This simplified pathway does not apply to the excluded product types specified in the regulation, including IVDs, sterile products, products with a measuring function, reusable surgical instruments, and innovative medical devices.

SFDA still has the right to request the complete technical documentation. Applicants should provide it within 10 days of receiving the request.

In addition, innovative medical devices have a separate documentation exemption mechanism, which should be assessed against the innovative device guidance and the relevant annexes of MDS-REQ1; it must not be confused with the ordinary low-risk simplified submission.

On 2 November 2026, SFDA also issued MDS-G020, the ‘Guidance on Recognized Standards for Medical Devices’, to support standard selection and preparation of conformity evidence in MDMA applications. Companies should use this guidance to verify the applicable technical standards and their recognition status.

Special reminder: the low-risk simplified submission does not exempt the manufacturer from the obligation to establish, maintain, and update the complete technical file.

[Legal basis] Article 4 and Annexes (3), (4), and (11) of MDS-REQ1 V6.0; MDS-G020 (2026-11-02).

Q10 Are local clinical trials in Saudi Arabia mandatory for registration?

Not all medical devices are required to conduct clinical trials again in Saudi Arabia, but manufacturers still need to provide sufficient clinical evaluation or performance evaluation evidence based on the product characteristics, risk class, and applicable regulations.

For non-IVD medical devices, the focus is on:

  • Clinical Evaluation;
  • Post-Market Clinical Follow-up (PMCF), where applicable;
  • The sufficiency and applicability of existing clinical evidence.

For IVD products, the focus is on performance evaluation, including applicable analytical performance and clinical performance evidence, as well as post-market performance follow-up requirements.

If a company plans to conduct medical device clinical trials or IVD performance studies in Saudi Arabia, the corresponding SFDA approval must be obtained under MDS-REQ2, and the applicable clinical trial standards followed.

Medical device clinical investigations should follow ISO 14155:2020; IVD performance studies should follow ISO 20916 and other applicable requirements.

Therefore, before registration, companies should first assess whether the existing clinical or performance evidence is sufficient, and only then decide whether additional studies are needed, rather than assuming that every product must undergo new clinical trials locally in Saudi Arabia.

[Legal basis] Annexes (6) and (7) of MDS-REQ1 V6.0; MDS-REQ2 V5.0 (2024-06-11; published on the SFDA website on 2025-06-22).

Q11 Can multiple models or multiple products be combined into a single MDMA application?

Yes, but the SFDA product bundling requirements must be met.

On 3 May 2026, SFDA issued MDS-G028 V1.0, ‘Guidance on Bundling Criteria for Medical Devices within a Single MDMA Application’.

This guidance explicitly supersedes the product bundling rules in the former Annex (15) of MDS-REQ1. It mainly covers the following types:

1. Medical Device Family

In general, the following must be met:

  • The same legal manufacturer;
  • The same intended use;
  • The same risk class;
  • Where GMDN codes exist, conformity with the same GMDN definition;
  • Common physical design, construction materials, and manufacturing processes;
  • A maximum of 5 technical files;
  • No more than 50 products in total within a single application.

For reusable surgical instruments and dental devices, MDS-G028 also sets dedicated family bundling conditions, such as functional or specialty-area requirements; the ordinary device family criteria cannot be applied directly.

2. Medical Device System

The main requirements are:

  • The same legal manufacturer;
  • The products are combined for use to achieve a common intended use;
  • The technical files, labelling, and IFUs should demonstrate the relationships among the system components;
  • Only one system per application;
  • A maximum of 5 technical files;
  • No more than 50 products in total, including accessories;
  • Where system components have different risk classes, the highest risk class applies.

3. Procedure Pack

The main requirements are:

  • The principal manufacturer of the procedure pack should be consistent, but component manufacturers may differ;
  • The procedure pack has the same intended use and specialty area;
  • The procedure pack has a consistent risk class;
  • A maximum of 5 technical files;
  • No more than 50 products in total;
  • Documentation on the procedure pack and each component should be submitted;
  • Components that need to be marketed separately should be applied for separately.

4. IVD Product Bundling

MDS-G028 sets dedicated bundling conditions for IVD products, mainly including:

  • The same legal manufacturer;
  • The same risk class;
  • The same intended use;
  • The same testing principle;
  • Conformity with the assay categories or groupings specified in the guidance;
  • A maximum of 5 technical files;
  • No more than 50 products in a single application, including accessories.

The guidance also provides a specific bundling exception for certain Class A general laboratory products, but not all Class A IVDs are exempt from the above conditions.

[Legal basis] SFDA MDS-G028 V1.0 (2026-05-03), explicitly superseding the former Annex (15) of MDS-REQ1 V6.0.

Part 3: Fees, Review Timelines, and Certificate Management

Q12 What are the official MDMA registration fees in Saudi Arabia?

According to the official MDMA fee document published by SFDA in January 2026, the fees for new applications are as follows:

Fee GroupRisk ClassOfficial Review Fee
FG1Class A15,000 SAR
FG2Class B19,000 SAR
FG3Class C21,000 SAR
FG4Class D23,000 SAR

The official fee document also states that the review period is 35-60 working days, depending on the product type, risk class, and the number of products included in a single application.

Fees for renewal and changes:

Application ItemOfficial Fee
MDMA renewal5,000 SAR
Adding a device5,000 SAR
Adding a model5,000 SAR
Changing the brand name5,000 SAR
Updating the product technical file5,000 SAR
Transitional period certificate letter5,000 SAR
Simple change of manufacturer name or address5,000 SAR
Labelling update only1,100 SAR
IFU update only1,100 SAR
Advertising material update only1,100 SAR
Change of product risk classificationFull fee of the corresponding risk class
Change of legal manufacturer name or addressFull fee of the corresponding risk class

Note that a simple information update of the manufacturer’s name or address is not the same as a change of the legal manufacturer entity; the applicable fee should be determined by the actual content of the change.

The fees above are official SFDA fees and do not include AR service fees, regulatory consulting fees, translation fees, or other third-party costs.

[Legal basis] Official SFDA document ‘Elevation Fees of Medical Device Marketing Authorization (MDMA)’, published in January 2026.

Q13 How long does MDMA review take? What are the rules on deficiency responses and application deletion?

1. Review timelines for new applications

According to the official fee document published by SFDA in January 2026:

  • Standard MDMA application: 35-60 working days;
  • Reliance pathway: 35-60 working days;
  • For reliance applications that meet the conditions with a complete dossier, the review can be shortened to 35 working days.

Actual review times are also affected by dossier completeness, product complexity, and deficiencies raised during the review process.

2. Deficiency response time

Under SFDA Announcement (8) 8/2019:

  • After an application is returned, the total deficiency response time across all three review cycles is 60 calendar days;
  • If the deficiencies are not completed within 60 days, the application may be deleted;
  • If an extension is justified, an extension request should be submitted to SFDA, and contact should be made via mdma.it@sfda.gov.sa as required.

3. Payment deadline

After receiving the SFDA payment notice, payment must be completed within 30 calendar days; overdue payment may result in deletion of the application.

4. Application deletion and fee refunds

If all issues raised by SFDA remain unresolved within the three review cycles, or the deficiency response deadline is exceeded, the application may be deleted and fees already paid are non-refundable.

Therefore, companies should complete a thorough technical documentation gap analysis before submission to avoid delays caused by missing documents, incomplete responses, or missed deadlines.

[Legal basis] SFDA MDMA fee document of January 2026; Announcement (8) 8/2019 (MDS-AN015); official SFDA FAQs.

Q14 How long is an MDMA certificate valid? How is renewal handled?

The validity period of an MDMA certificate should follow the term stated on the certificate finally issued by SFDA; it is not advisable to state a fixed 3-year term for all products.

SFDA’s earlier official fee documents included provisions on MDMA validity, involving factors such as the product category and the validity of the original approval documents. Companies should confirm the validity period based on the current application pathway and the final certificate.

On renewal, the previously stated timing of applying 90 days in advance can be retained: companies should submit the renewal application through the electronic system well before the certificate expires, to avoid disruption of commercial distribution caused by an expired certificate.

According to the official SFDA fee document of January 2026, the MDMA renewal fee is 5,000 SAR.

Renewal should also address:

  • Whether the product has undergone significant changes;
  • Whether the manufacturer information has changed;
  • Whether the labelling and IFU need to be updated;
  • Whether the related technical files remain valid;
  • Whether the applicable quality system and post-market surveillance requirements continue to be met.

[Legal basis] Article 5 and Annex (12) of MDS-REQ1 V6.0; official SFDA MDMA fee document; related renewal announcements and GHAD system requirements.

Q15 After obtaining the MDMA, can the product, labelling, and IFU be modified? How are changes filed?

Yes, but it must first be determined whether the change is significant or non-significant.

SFDA MDS-G012 V1.0, ‘Guidance on MDMA – Significant and Non-Significant Changes’, sets out the corresponding procedures.

Change TypeHandlingTime Limit
Significant ChangeFile through the GHAD system; SFDA approval requiredReport within 10 days of the change
Non-significant ChangeNotify SFDA via the designated email; no prior approval requiredNotify within 30 days of the change

Significant changes:

The manufacturer should update the relevant MDMA application through the GHAD system and submit the Medical Device Change Form with supporting documents. Products affected by the significant change may only be supplied after SFDA approval is obtained.

Non-significant changes:

The manufacturer should send an email within 30 days of the change to: MDMA.IT@sfda.gov.sa

The email subject should state the MDMA certificate number, and the change form and related materials should be submitted in accordance with the guidance.

If only a brief change summary is submitted first, the complete documentation should be provided within 90 days of the change. SFDA may also require the corresponding application information to be updated in the GHAD system.

Change fees should follow SFDA’s latest fee document; quoting based solely on the fee categories of earlier announcements is no longer appropriate.

[Legal basis] MDS-G012 V1.0 (2023-03-22); MDS-REQ1 V6.0; SFDA MDMA fee document of January 2026.

Part 4: UDI, Labelling, and Post-Market Surveillance

Q16 Does Saudi Arabia have UDI requirements? When do they become mandatory?

Yes. Saudi Arabia has established requirements for medical device unique identification (UDI) and the management of the Saudi-DI database.

1. Issuing agencies

The UDI issuing agencies recognized by SFDA include:

  • GS1;
  • HIBCC;
  • ICCBBA.

2. UDI composition

The UDI mainly consists of two parts:

  • UDI-DI: the Device Identifier, used to identify a specific device and link it to the Saudi-DI database;
  • UDI-PI: the Production Identifier, covering the batch number, serial number, manufacturing date, expiry date, software version, and other applicable information.

3. Label and packaging requirements

The UDI should be presented on the product label and the corresponding packaging levels in both human-readable form (HRI) and automatic identification and data capture form (AIDC) as required. Reusable devices also require direct marking (DM) as required.

4. Phased implementation dates

Risk ClassUDI Implementation Date
Classes B, C, and D2023-09-01
Class A2024-09-01

The Saudi-DI database is already in operation. Companies should ensure that UDI-DI and related product information meet the database submission and maintenance requirements.

For transitional treatment of legacy imported products, the corresponding SFDA announcement and the actual import situation of the product should be checked; a specific transitional arrangement must not be read as a one-year grace period for all products.

[Legal basis] MDS-REQ7 V4.0; the official SFDA Saudi-DI database and related UDI announcements.

Q17 What are the language requirements for Saudi labels and IFUs? What content must be labelled?

Under Principle 23 in Annex (1) of MDS-REQ1, the labelling and IFU must meet the applicable language requirements based on the intended users and the way the product is used.

1. Language requirements

  • For devices intended for lay persons, the information supplied by the manufacturer should be provided in both Arabic and English;
  • For devices intended for lay persons, the device name on the label should also include an Arabic name transliterated from the English pronunciation;
  • For products intended for healthcare professionals, documentation in the applicable languages should be provided according to the applicable requirements.

2. Key label information

This includes:

  • The device name;
  • Information sufficient to identify the product and the package contents;
  • The manufacturer’s name and registered address;
  • Where applicable, information on any medicinal substance, or human or animal tissue and cells;
  • Where applicable, warning information on CMR substances and endocrine disruptors;
  • The UDI carrier.

3. IFU requirements

Class A and B products that can be used safely without an IFU may be exempt from supplying one as provided. Electronic IFUs (e-IFU) should follow Annex (10) of MDS-REQ1 and the applicable conditions.

4. SFDA identity

Product labels and advertising materials must not use the SFDA name or logo without authorization. Products may display the Saudi National Listing Number as provided.

[Legal basis] MDS-REQ1 V6.0 Annex (1), EP 23.1/23.2, and Annex (10); MDS-REQ7.

Q18 Within what time limits must adverse events or recalls be reported to SFDA?

Under MDS-REQ11, ‘Post-Market Surveillance Requirements for Medical Devices’, manufacturers, ARs, and other responsible establishments should report promptly according to the severity of the event.

1. Adverse event reporting deadlines

Adverse Event TypeReporting Deadline
Serious public health threat2 days
Events that may directly or indirectly lead to death or serious injury10 days
Other reportable events30 days

2. FSCA – Field Safety Corrective Actions

For FSCAs affecting the Saudi market, the following also applies:

TaskRequired Time Limit
Report FSCAs affecting Saudi Arabia to the NCMDR2 days
Respond to SFDA safety alerts or inquiries5 days
Notify importers, distributors, healthcare facilities, and users5 days
Submit the FSCA implementation plan5 days
Implementation expected to exceed 90 daysSubmit progress reports as required

3. Related responsibilities

Manufacturers, ARs, importers, and distributors should designate a person responsible for communicating with SFDA and establish procedures for complaints, adverse events, recalls, and FSCAs. Healthcare facilities should also designate NCMDR contact persons as required.

Companies should not activate reporting procedures only when an adverse event occurs in Saudi Arabia; safety events occurring abroad that involve products on the Saudi market should also be reported to SFDA as required.

[Legal basis] MDS-REQ11 V2.0 (published on the SFDA website on 2023-03-28).

Q19 Do medical device advertisements, social media promotion, or promotional events in Saudi Arabia require approval?

Yes.

Article 24 and Article 25 of the Medical Devices Law, and MDS-REQ8 V4.0, govern medical device advertising approval, awareness campaigns, and charitable campaigns.

On 20 July 2026, SFDA issued MDS-REQ8 V4.0, ‘Requirements for Obtaining SFDA Approval for Advertisement and Launching Awareness and Charitable Campaigns for Medical Devices’.

The new version clarifies two advertising approval pathways.

Pathway 1: submit together with the MDMA technical documentation

The manufacturer or AR may submit advertising materials as part of the MDMA application dossier.

  • Review timeline: as per the MDMA review requirements;
  • Validity of the advertising approval: aligned with the MDMA certificate validity;
  • Fees: as per the applicable MDMA application fee rules.

Pathway 2: apply separately for advertising approval

Apply separately through the SFDA electronic services portal.

Advertising AudienceOfficial FeeApproval Time
General public3,000 SAR10 days
Healthcare professionals6,000 SAR10 days
  • Initial approval validity: 1 year;
  • Extension or renewal may be requested;
  • Extension or renewal for a term of up to 5 years;
  • Applicable fees payable according to the requested term.

The new advertising requirements also include:

  • A product must hold a valid MDMA before advertising may be conducted as required;
  • Advertising content must not include product uses or claims not approved by SFDA;
  • The names and logos of SFDA or other regulatory authorities must not be used;
  • Advertising must not disparage other companies’ products, nor contain competitive comparisons with other companies’ products;
  • Advertising materials targeted at the general public should be in Arabic;
  • Advertising materials targeted at healthcare professionals should be in English;
  • Each distinct advertising format should be submitted as a separate application as required.

Special requirements for social media promotion:

  • Websites and social media advertising targeted at the Saudi general public may require SFDA advertising approval, even if the website or platform is registered outside Saudi Arabia;
  • When promoting through social media content creators, the content creators must hold a Mawthooq advertising content creation license;
  • The visual, audio, or text content to be published should be sent to AD.L@sfda.gov.sa at least 12 hours before publication, together with the advertiser’s name, social media accounts, and the planned publication time;
  • An advertising cooperation contract should be signed between the advertiser and the content creator, and the contract and related materials submitted as required;
  • Replies in the comment sections of social media advertising must not contain unapproved product information.

In addition, product introduction lectures or seminars held for healthcare professionals should be submitted for approval at least 14 working days in advance.

[Legal basis] Article 24 and Article 25 of the Medical Devices Law; MDS-REQ8 V4.0 (2026-07-20).

Part 5: Import and Customs Clearance

Q20 What is required to clear medical devices at the Saudi port of entry?

Under MDS-REQ5, ‘Requirements on Importation and Shipments Clearance of Medical Devices and Supplies’ V6.0 (2023-07-19), importing medical devices for commercial distribution mainly requires the following:

1. Product and establishment licensing

In general:

  • The product holds a valid MDMA;
  • The importer holds a valid Importer License;
  • The foreign manufacturer’s products have a valid AR license as required;
  • The goods complete import and customs clearance release procedures as required by SFDA.

Among these, for products meeting specific low-risk conditions, the corresponding exemption provisions should be checked further.

2. Import licensing for chemical medical devices and IVDs

For chemicals that are themselves medical devices or medical supplies, including related IVD products, the corresponding Importation License/Permission should be obtained as required by MDS-REQ5. This license is usually valid for 1 year, and the MDMA certificate validity and import quantity requirements must also be considered.

Note that this refers to chemicals classified as medical devices or medical supplies; it must not be read broadly as requiring an additional chemical import license for every ordinary medical device that contains chemical ingredients.

3. Shelf-life requirements

Product Shelf LifeMinimum Remaining Shelf Life on Arrival
Less than 1 yearNot less than 40%
More than 1 yearNot less than 7 months

For products with a shelf life of exactly one year, neither of the two provisions above is explicit; it is advisable to confirm with SFDA before actual clearance rather than making an assumption.

4. Transport requirements for temperature- and humidity-sensitive products

If the manufacturer’s IFU requires specific temperature or humidity control during transport or storage, the following is needed:

  • Each package and each shipment equipped with the corresponding electronic temperature and humidity data loggers;
  • Loggers activated at the time of shipment;
  • Detailed records readable without dedicated software upon arrival at the port;
  • Logger serial numbers recorded on shipping documents such as invoices and bills of lading.

5. Labelling requirements

Imported product labels must comply with SFDA requirements and be consistent with the labels previously submitted to SFDA (where applicable). SFDA may sample and inspect or test products at the port based on risk assessment.

6. Free Sale Certificate (FSC)

Where the relevant conditions are met, manufacturers may apply to SFDA for a Free Sale Certificate under Annex (6) of MDS-REQ5. The FSC is valid for 1 year, and the validity of the related MDMA certificate must also be considered.

7. Transport and storage management

Beyond import clearance, companies should also note MDS-REQ12, ‘Requirements for Transporting and Storage of Medical Devices’. This document applies to manufacturers, ARs, importers, distributors, and medical device warehousing establishments. The main requirements include:

  • Establishing transport and storage procedures according to the manufacturer’s requirements;
  • Warehousing establishments obtaining the applicable SFDA warehouse license or third-party warehousing license;
  • Establishing monitoring and temperature mapping validation arrangements for storage areas requiring temperature and humidity control;
  • Transport vehicles and transport processes meeting the temperature, humidity, and other environmental requirements specified by the manufacturer;
  • Establishing product traceability, inventory management, returns, and recall quarantine procedures.

Therefore, companies should not focus only on whether the product has obtained an MDMA; the importer, warehouse, and transport links must also comply with the relevant Saudi requirements.

[Legal basis] MDS-REQ5 V6.0 (2023-07-19); MDS-REQ9 V2.0; MDS-REQ12 V2.0 (2024-12-15).

Part 6: Additional Q&A on Saudi Registration Policy Updates in 2026

Q21 How should companies assess whether the newly issued Reliance pathway in 2026 applies to them?

Companies can start from the following four aspects:

First, whether an effective approval from a recognized regulatory authority has been obtained.

The reference regulatory authorities currently listed in MDS-G030 include:

  • US FDA;
  • EU / EEA competent authorities;
  • Health Canada of Canada;
  • TGA of Australia;
  • PMDA of Japan;
  • MHRA of the United Kingdom.

Second, whether the product is consistent with the reference-approved product.

The following should be checked in particular:

  • Product design;
  • Manufacturing process;
  • Intended use;
  • Product specifications;
  • Applicable models;
  • Labelling and IFU.

Third, whether any of the exclusion situations specified in the guidance exist.

For example, products approved through self-declaration, products approved mainly through substantial equivalence, custom-made devices, and products with significant post-market safety issues.

For SaMD and AI-based medical devices, applicability must also be confirmed with SFDA’s specific judgement.

Fourth, whether Saudi local requirements can be met.

Even with FDA or CE approvals in hand, Saudi requirements on electrical safety, labelling, language, transport, and storage must still be checked.

Recommendation: before starting Saudi registration, companies can run a Reliance suitability assessment, compare the standard MDMA route with the reliance review route, and choose the registration pathway that better fits the product.

Q22 Can IVD products with multiple models or multiple assay items be combined into one application?

Yes, but the dedicated IVD bundling rules of MDS-G028 must be applied.

The main conditions include:

  • The same legal manufacturer;
  • The same risk class;
  • The same intended use;
  • The same testing principle;
  • Conformity with the assay categories or groupings specified in the guidance;
  • A maximum of 5 technical files per application;
  • A maximum of 50 products per application, including accessories.

The main IVD groupings listed in the guidance include:

  • Blood grouping assays;
  • Tissue typing;
  • Cancer and non-malignant tumor marker assays;
  • Human genetic testing;
  • Infection and immune status marker assays;
  • Non-infectious pathological and physiological marker assays and related disease testing;
  • Quality control materials without assigned quantitative or qualitative values.

In addition, certain Class A general laboratory products may qualify for a special bundling arrangement when the conditions specified in the guidance are met.

Therefore, IVD companies should not assume that products can be combined into one application simply because they belong to the same series or share the same brand. The testing principle, testing purpose, risk class, and technical files should be checked item by item.

Q23 What are the special requirements for promoting medical devices on TikTok, Instagram, YouTube, and other social media in Saudi Arabia?

Special attention should be paid to the social media advertising requirements of MDS-REQ8 V4.0.

The main points include:

  • Internet and social media advertising targeted at the Saudi general public should obtain SFDA approval as required;
  • Even if the website or social media platform is registered outside Saudi Arabia, the requirement may apply as long as the advertising targets the general public within Saudi Arabia;
  • When using social media content creators for product promotion, the content creators should hold a Mawthooq license;
  • Advertising materials should be submitted to SFDA in advance, and the content to be published should be sent to the designated email at least 12 hours before publication;
  • The advertising cooperation contract should specify the advertising content, display time, publication platforms, and contract term;
  • Published content must not exceed the product uses and claims approved by SFDA;
  • The advertising language should meet the target audience requirements: Arabic for the general public and English for healthcare professionals.

This means companies cannot simply transfer promotional videos, product introductions, or influencer content already published in China or other countries to the Saudi market. The advertising content should first be checked against Saudi local approval requirements.

Part 7: Key Takeaways and Pre-Registration Preparation for Saudi Registration

As of November 2026, the Saudi medical device regulatory framework covers marketing authorization, reliance review, product bundling, quality management, UDI, advertising, and post-market surveillance in a fairly complete manner.

In this round of updates, companies should pay particular attention to the following changes:

  • Reliance review: MDS-G030 was issued in September 2026, providing a new registration pathway for eligible products;
  • Product bundling: MDS-G028 was issued in May 2026, superseding the former Annex 15 of MDS-REQ1 and further clarifying bundling conditions for non-IVD and IVD products;
  • Advertising approval: MDS-REQ8 V4.0 was issued in July 2026, clarifying the two advertising approval pathways, fees, and social media promotion requirements;
  • Official fees: the January 2026 fee document updated the fees for new MDMA applications, renewal, and changes;
  • Quality systems and transport and storage: companies need to meet MDS-REQ10, MDS-REQ12, and other related requirements at the same time.

If a company plans to enter the Saudi market, the following work is recommended before starting registration:

  • Product classification and determination of applicable regulations;
  • Feasibility assessment of the standard MDMA route versus the Reliance route;
  • Technical documentation gap analysis;
  • Confirmation of Saudi AR and importer qualifications;
  • Compliance check of UDI and labelling;
  • Assessment of transport, storage, and post-market surveillance requirements.

Entering the Saudi medical device market requires not only a marketing authorization, but also continuous compliance with local quality system, import, labelling, and post-market surveillance requirements.

Part 8: Official Regulatory and Reference Checkpoints

The following are the main SFDA regulations, guidance documents, and announcements on which this article is based. For actual submissions, the current versions on the SFDA website and the GHAD system requirements prevail.

Official DocumentVersion / DateOfficial Entry Point
Medical Devices LawM/54SFDA regulations catalog: https://www.sfda.gov.sa/en/regulations
MDS-REQ1V6.0 / 2021-12-19Official PDF: https://www.sfda.gov.sa/sites/default/files/2021-12/REQ1En_0.pdf
MDS-REQ2V5.0 / 2024-06-11Official PDF: https://www.sfda.gov.sa/sites/default/files/2025-06/MDS-REQ2_En_V5%202025.pdf
MDS-REQ5V6.0 / 2023-07-19Official PDF: https://sfda.gov.sa/sites/default/files/2023-07/MDS-REQ5E.pdf
MDS-REQ7UDI requirementsOfficial Saudi-DI system: https://udi.sfda.gov.sa/
MDS-REQ8V4.0 / 2026-07-20Official PDF: https://oldsfda.sfda.gov.sa/sites/default/files/2026-07/MDS-REQ%208_En_V4.pdf
MDS-REQ9V2.0 / 2025-01-15Official PDF: https://beta.sfda.gov.sa/sites/default/files/2025-03/MDS-REQ%209_En_V2.pdf
MDS-REQ10V2.0 / 2025-01-27Official PDF: https://www.sfda.gov.sa/sites/default/files/2026-10/MDS-REQ10EE.pdf
MDS-REQ11V2.0SFDA official regulations page: https://www.sfda.gov.sa/sites/default/files/2023-05/MDS_REQ%2011_V2_En.pdf
MDS-REQ12V2.0 / 2024-12-15Official PDF: https://www.sfda.gov.sa/sites/default/files/2026-08/MDS-REQ12E_0.pdf
MDS-G008Medical device classification guidanceSFDA official guidance catalog: https://sfda.gov.sa/ar/guide/15903
MDS-G012V1.0 / 2023-03-22Official PDF: https://sfda.gov.sa/sites/default/files/2023-03/MDS-G012A.pdf
MDS-G028V1.0 / 2026-05-03Official PDF: https://beta.wideip.sfda.gov.sa/sites/default/files/2026-05/MDS-G28.pdf
MDS-G030V1.0 / 2026-09-09Official PDF: https://www.sfda.gov.sa/sites/default/files/2026-09/MDS-G030.pdf
MDS-G020Published on the SFDA website on 2026-11-02SFDA official guidance catalog: https://sfda.gov.sa/ar/guide/15903
Official MDMA fee documentJanuary 2026Official PDF: https://www.sfda.gov.sa/sites/default/files/2026-01/MDMAFee4En.pdf
Announcement (8) 8/2019MDS-AN015Official PDF: https://sfda.gov.sa/sites/default/files/2019-12/SDFA-MDSAN015.pdf

Disclaimer: This article is based on the SFDA regulations, guidance documents, announcements, and fee documents publicly available and verifiable as of 10 November 2026. It is provided for medical device market access information purposes only and does not constitute legal advice or any registration commitment regarding specific products. Regulations and official system requirements may continue to be updated; actual submissions should follow the latest SFDA publications, GHAD system requirements, and the final position of the regulator.

Grzan

Author:Grzan

Get the latest global medical device development and regulatory news, insights and resources.

WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail